Despite the efficacy of EGFR-TKIs, emerging evidence suggests that patients with advanced NSCLC and EGFR Exon 20 insertions (Exon 20ins) exhibit significant resistance to these inhibitors (4). This evidence concerns the gene EGFR and non-small cell lung carcinoma.